Lilly gets emergency OK for COVID-19 treatment bamlanivimab

• Eli Lilly (NYSE:LLY) has received emergency use authorization from the FDA for bamlanivimab, a treatment for mild-to-moderate COVID-19 in adult and pediatric patients.
• Lilly says it will begin shipping the treatment immediately to AmerisourceBergen (NYSE:ABC), which will distribute it as directed by the government's allocation program. The government will allocate 300,000 doses to high-risk patients at no out-of-pocket cost.
• Safety and effectiveness continue to be evaluated, but bamlanivimab was shown in clinical trials to reduce COVID-19 hospitalization and ER visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo.
• It's not authorized for patients who are hospitalized or require oxygen therapy.
• https://seekingalpha.com/news/3634128-eli-lilly-gets-emergency-ok-for-covidminus-19-treatment-bamlanivimab-sharesplus-4_7